Revive Therapeutics Advances Biodefence Strategy with Bucillamine

Revive Therapeutics Ltd. announced its strategy to enhance a medical countermeasure portfolio emphasizing bucillamine. Building on positive findings from a DRDC study, Revive plans to pursue government-supported development, expand intellectual property, and explore complementary therapeutics.

The study compared bucillamine to NAC in preserving hippocampal GABA receptor density, noting no pulmonary hemorrhage in the bucillamine group. CEO Michael Frank stated the company's plan to harness these results in Canada, the U.S., and allied markets, aiming for long-term growth.

Potential applications for bucillamine include nerve-agent exposure, pesticide poisoning, and pandemic preparedness. These align with governmental frameworks for funding and stockpiling medical countermeasures. Revive aims to confirm research signals with DRDC, develop government pathways, and solidify intellectual property to support its strategy.